Fusion Antibodies (LON:FAB) Stock Falls 38.5% – Here’s Why

Fusion Antibodies plc (LON:FAB) shares were down 38.5% during trading on Thursday. The company traded as low as GBX 4.70 and last traded at GBX 6. 7,380,445 shares were traded during trading, an increase of 1,568% from the average daily volume of 442,459 shares. The stock had previously closed at GBX 9.75.

Fusion Antibodies Stock Performance

The company has a debt-to-equity ratio of 20.41, a quick ratio of 2.36 and a current ratio of 2.82. The stock has a fifty day simple moving average of GBX 10.99 and a two-hundred day simple moving average of GBX 11.86. The stock has a market capitalization of £7.51 million, a price-to-earnings ratio of -6.00 and a beta of 1.24.

Fusion Antibodies (LON:FAB) last announced its quarterly earnings data on Monday, September 14th. The company reported GBX (1.20) earnings per share (EPS) for the quarter. Fusion Antibodies had a negative net margin of 54.45% and a negative return on equity of 97.87%. Analysts forecast that Fusion Antibodies plc will post -130.00 earnings per share for the current fiscal year.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.